Androgen receptor CAG polymorphism and the risk of benign prostatic hyperplasia in a Brazilian population

Androgen receptor CAG polymorphism and the risk of benign prostatic hyperplasia in a Brazilian population

Benign prostatic hyperplasia (BPH) is a very frequent age-related proliferative abnormality in men. Polymorphic CAG repeat in the androgen receptor (AR) can alter transactivation of androgen-responsive genes and potentially influence BPH risk. We investigated the association between CAG repeat length and risk of BPH in a case-control study of a Brazilian population. We evaluated 214 patients; 126 with BPH and 88 healthy controls. DNA was extracted from peripheral leucocytes and the AR gene was analyzed using fragment analysis. Hazard ratio (HR) and 95% confidence interval were estimated using logistic regression models. Mean CAG length was not different between patients with BPH and controls. The CAG repeat length was examined as a categorical variable (CAG < 21 vs. CAG &gt; 21 and CAG < 22 vs. CAG &gt; 22) and did not differ between the control vs. the BPH group. We found no evidence for an association between AR CAG repeat length in BPH risk in a population-based sample of Brazilians.

Saved in:
Bibliographic Details
Main Authors: Biolchi,Vanderlei, Silva Neto,Brasil, Koff,Walter, Brum,Ilma Simoni
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Urologia 2012
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382012000300010
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Benign prostatic hyperplasia (BPH) is a very frequent age-related proliferative abnormality in men. Polymorphic CAG repeat in the androgen receptor (AR) can alter transactivation of androgen-responsive genes and potentially influence BPH risk. We investigated the association between CAG repeat length and risk of BPH in a case-control study of a Brazilian population. We evaluated 214 patients; 126 with BPH and 88 healthy controls. DNA was extracted from peripheral leucocytes and the AR gene was analyzed using fragment analysis. Hazard ratio (HR) and 95% confidence interval were estimated using logistic regression models. Mean CAG length was not different between patients with BPH and controls. The CAG repeat length was examined as a categorical variable (CAG < 21 vs. CAG &gt; 21 and CAG < 22 vs. CAG &gt; 22) and did not differ between the control vs. the BPH group. We found no evidence for an association between AR CAG repeat length in BPH risk in a population-based sample of Brazilians.

Similar Items